Influence of seizures on early development in tuberous sclerosis complex.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Epilepsy & Behavior

• Publication date

  2017-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.yebeh.2017.02.007PMID 28457992PMCID PMC5497719
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC.

  2016cited by this paper
• Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.

  2016cited by this paper
• Long-term treatment of epilepsy with everolimus in tuberous sclerosis

  2016cited by this paper
• Neurological and neuropsychiatric aspects of tuberous sclerosis complex.

  2015cited by this paper
• Autism spectrum disorder in tuberous sclerosis complex: searching for risk markers

  2015cited by this paper
• Everolimus for subependymal giant cell astrocytoma: 5‐year final analysis

  2015cited by this paper
• Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the Tuberous Sclerosis 2000 Study

  2015cited by this paper
• Early developmental trajectories associated with ASD in infants with tuberous sclerosis complex

  2014cited by this paper
• Intellectual development before and after the onset of infantile spasms: A controlled prospective longitudinal study in tuberous sclerosis

  2014cited by this paper
• Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference.

  2013cited by this paper
• Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

  2013cited by this paper
• Epilepsy in TSC: Certain etiology does not mean certain prognosis

  2013cited by this paper
• Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

  2013cited by this paper
• Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex.

  2011cited by this paper
• Cerebral tuber count and its impact on mental outcome of patients with tuberous sclerosis complex

  2011cited by this paper
• The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management

  2011cited by this paper
• Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex

  2011cited by this paper
• The new ILAE classification

  2010cited by this paper
• Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

  2010cited by this paper
• Early control of seizures improves long-term outcome in children with tuberous sclerosis complex.

  2010cited by this paper
• The natural history of epilepsy in tuberous sclerosis complex

  2009cited by this paper
• Characterization of Autism in Young Children With Tuberous Sclerosis Complex

  2008cited by this paper
• Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis

  2008cited by this paper
• Cognitive impairment in tuberous sclerosis complex is a multifactorial condition

  2008cited by this paper
• The Autism Observation Scale for Infants: Scale Development and Reliability Data

  2008cited by this paper
• Cognitive prognosis of patients with tuberous sclerosis complex

  2007cited by this paper
• Cognitive deficits in Tsc1+/−mice in the absence of cerebral lesions and seizures

  2007cited by this paper
• Neuroepileptic correlates of autistic symptomatology in tuberous sclerosis.

  2004cited by this paper
• A prospective longitudinal study of early cognitive development in tuberous sclerosis

  2004cited by this paper
• Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex

  2003cited by this paper
• Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex.

  2002cited by this paper
• The Autism Diagnostic Observation Schedule—Generic: A Standard Measure of Social and Communication Deficits Associated with the Spectrum of Autism

  2000cited by this paper
• Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance

  1998cited by this paper
• Mullen Scales of Early Learning

  1997cited by this paper
• Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

  1994cited by this paper
• Epidemiology of Tuberous Sclerosis

  1991cited by this paper
• Causes of death in patients with tuberous sclerosis.

  1991cited by this paper
• Criteria for diagnosis

  1946cited by this paper

• Early Vocal Development in Tuberous Sclerosis Complex Predicts Language but Not Autism Outcomes.

  2026cites this paper
• Tuberous sclerosis complex: clinical insights into communication and swallowing abilities: a case report

  2026cites this paper
• Neurodevelopmental Outcomes From the PREVeNT Trial.

  2025cites this paper
• An interpretable machine learning approach for predicting drug-resistant epilepsy in children with tuberous sclerosis complex

  2025cites this paper
• Tuberous sclerosis complex: Clinical, genetic and 7T-MRI neuroimaging findings.

  2025cites this paper
• Pediatric refractory epilepsy related to tuberous sclerosis complex: A retrospective-cohort study of diagnosis and treatment.

  2025cites this paper
• Developmental Outcome at 36 Months in Tuberous Sclerosis: Are There any Modifiable Predictors?

  2025cites this paper
• Protocol for EpiCom: A phase 3b/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)

  2025cites this paper
• Mechanistic strategies for secondary prevention of developmental and epileptic encephalopathy in children with tuberous sclerosis complex

  2025cites this paper
• Congenital Localized Hypopigmentation Disorders as a Clue of Severe Neurologic Involvement: An Update Review

  2025cites this paper
• Neuronal hyperactivity becomes mTORC1 independent due to transcriptional changes in tuberous sclerosis complex disease models

  2025cites this paper
• Neuropsychiatric disorders in Chinese pediatric tuberous sclerosis complex patients associated with drug-resistant epilepsy: A TAND checklist-based survey

  2025cites this paper
• Tuberous Sclerosis Complex: An updated in the treatment of epilepsy for early careers.

  2025cites this paper
• Burden of illness in tuberous sclerosis complex-associated epilepsy: a systematic literature review of epidemiology, health-related quality of life, costs and resource use

  2025influential citation
• Investigation of Gait Characteristics and Kinematic Deviations in Rare Genetic Disorders with Instrumented Gait Analysis

  2025cites this paper
• Neuropsychiatric profile in tuberous sclerosis complex patients with epilepsy

  2025cites this paper
• Limited Utility for Head Ultrasounds in the Evaluation of Tuberous Sclerosis Complex.

  2025cites this paper
• "Tuberous sclerosis in Greece: A national cohort study on clinical features and rare manifestations".

  2025cites this paper
• Infantile Spasms (West Syndrome): Integrating Genetic, Neurotrophic, and Hormonal Mechanisms Toward Precision Therapy

  2025cites this paper
• The correlation between tuber burden and epilepsy onset in children with tuberous sclerosis complex.

  2025cites this paper
• Lesions Associated With Autism Symptoms Map to a Cerebellar Brain Network in Tuberous Sclerosis Complex

  2025cites this paper
• Clinical outcomes following stereotactic MRI-guided laser ablation in children with tuberous sclerosis complex and intractable epilepsy.

  2025cites this paper
• Tuberous sclerosis complex: Diagnostic features, surveillance, and therapeutic strategies.

  2024cites this paper
• Risk Factors for Psychiatric Disorders in Pediatric Patients with Tuberous Sclerosis Complex

  2024cites this paper
• Vigabatrin‐associated brain magnetic resonance imaging abnormalities and clinical symptoms in infants with tuberous sclerosis complex

  2024cites this paper
• Evolving treatment strategies for early-life seizures in Tuberous Sclerosis Complex: A review and treatment algorithm.

  2024cites this paper
• Accumulated seizure burden predicts neurodevelopmental outcome at 36 months of age in patients with tuberous sclerosis complex

  2024influential citation
• Premature cognitive decline in a mouse model of tuberous sclerosis

  2024cites this paper
• The role of the TSC Alliance in advancing therapy development: a patient organization perspective

  2024cites this paper
• Have epilepsy outcomes changed for children with tuberous sclerosis complex in Queensland, Australia?

  2024cites this paper
• Association of earlier surgery with improved postoperative language development in children with tuberous sclerosis complex.

  2024cites this paper
• Drug-Resistant Epilepsy in Tuberous Sclerosis Complex Is Associated With TSC2 Genotype: More Findings From the Preventing Epilepsy Using Vigatrin (PREVeNT) Trial.

  2024cites this paper
• Seizure freedom but not epilepsy surgery is associated with fewer neuropsychiatric difficulties in patients with tuberous sclerosis.

  2024influential citation
• Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results

  2024cites this paper
• A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales

  2024cites this paper
• Autism and Epilepsy.

  2024cites this paper
• Interpreting motor function outcomes in young males with Duchenne muscular dystrophy

  2024cites this paper
• Retrospective analysis of presymptomatic treatment in Sturge–Weber syndrome

  2024cites this paper
• Commentary Regarding the Results of the PREVeNT and EPISTOP Trials

  2023cites this paper
• Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy

  2023cites this paper
• A single-center observational study on long-term neurodevelopmental outcomes in children with tuberous sclerosis complex

  2023cites this paper
• Early therapeutic intervention guided by electroencephalography surveillance in infants with tuberous sclerosis complex

  2023cites this paper
• Early development and epilepsy in tuberous sclerosis complex: A prospective longitudinal study

  2023influential citation
• Is tuberous sclerosis complex-associated autism a preventable and treatable disorder?

  2023cites this paper
• The profile of epilepsy and its characteristics in children with neurocutaneous syndromes

  2023cites this paper
• Epidemiology of focal onset seizures in children aged >1 month to 4 years in Europe, United States, and Canada: A literature review.

  2023cites this paper
• Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy.

  2023cites this paper
• Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial

  2023cites this paper
• Paradigm shift in the treatment of tuberous sclerosis: effectiveness of everolimus.

  2023cites this paper
• Understanding the impact of tuberous sclerosis complex: development and validation of the TSC-PROM

  2023cites this paper
• Understanding speech and language in tuberous sclerosis complex

  2023cites this paper
• Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age

  2023cites this paper
• The TSC2 c.2742+5G>A variant causes variable splicing changes and clinical manifestations in a family with tuberous sclerosis complex

  2023cites this paper
• Treatment-Resistant Epilepsy and Tuberous Sclerosis Complex: Treatment, Maintenance, and Future Directions

  2023cites this paper
• Epilepsy Severity Is Associated With Head Circumference and Growth Rate in Infants With Tuberous Sclerosis Complex.

  2023cites this paper
• Kinase Inhibitors in Genetic Diseases

  2023cites this paper
• The research landscape of tuberous sclerosis complex–associated neuropsychiatric disorders (TAND)—a comprehensive scoping review

  2022cites this paper
• Everolimus as a therapeutic option in refractory epilepsy in children with tuberous sclerosis: a systematic review

  2022cites this paper
• Racial differences in the dermatological manifestations of tuberous sclerosis complex and the potential effects on diagnosis and care

  2022cites this paper
• Aspects of autism spectrum disorder and correlation with neuroimaging findings in tuberous sclerosis complex.

  2022cites this paper
• Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies

  2022cites this paper
• Describing autism spectrum disorder in tuberous sclerosis complex: Challenges and future opportunities

  2022cites this paper
• Comparison of outcomes after stereoelectroencephalography and subdural grid monitoring in pediatric tuberous sclerosis complex.

  2022cites this paper
• Resective epilepsy surgery for West syndrome: The Hypsarrhythmic Asymmetric Scoring Scheme is a determining predictor of seizure outcome.

  2022cites this paper
• Epilepsy and Language Development in 8–36-Month-Old Toddlers with Tuberous Sclerosis Complex

  2022cites this paper
• Changing the outcome in genetic brain disorders

  2022cites this paper
• Epileptic spasms are associated with increased stereo‐electroencephalography derived functional connectivity in tuberous sclerosis complex

  2022cites this paper
• Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex

  2022cites this paper
• Current role of surgery for tuberous sclerosis complex‐associated epilepsy

  2022cites this paper
• 3D deep neural network to automatically identify TSC structural brain pathology based on MRI

  2022cites this paper
• Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6

  2022cites this paper
• Limited utility of structural MRI to identify the epileptogenic zone in young children with tuberous sclerosis

  2022cites this paper
• Profile of Autism Spectrum Disorder in Tuberous Sclerosis Complex: Results from a Longitudinal, Prospective, Multisite Study

  2021cites this paper
• Early Vocal Development in Tuberous Sclerosis Complex

  2021cites this paper
• Factors associated with autism spectrum disorder in children with tuberous sclerosis complex: a systematic review and meta‐analysis

  2021influential citation
• Seizures and Epilepsy in Autism Spectrum Disorder.

  2021cites this paper
• The role of new medical treatments for the management of developmental and epileptic encephalopathies: Novel concepts and results

  2021cites this paper
• Clinical and Neurological Course of Tuberous Sclerosis Complex in Children and Adolescents

  2021cites this paper
• Surgery for drug-resistant tuberous sclerosis complex-associated epilepsy: who, when, and what.

  2021cites this paper
• Epilepsy in adult patients with tuberous sclerosis complex

  2021cites this paper
• Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes

  2021cites this paper
• mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus

  2021cites this paper
• Can we prevent epilepsy? Yes, we can!

  2021cites this paper
• Hyperactive behaviour in Angelman syndrome: the association with sleep problems and age of epilepsy onset.

  2021cites this paper
• Antiepileptogenesis and disease modification: Clinical and regulatory issues

  2021cites this paper
• Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives

  2021cites this paper
• Epilepsy associated with tuberous sclerosis complex in childhood: Long-term outcome in children after epilepsy surgery and children non-eligible for epilepsy surgery.

  2021cites this paper
• Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine

  2021cites this paper
• Epilepsy Is Heterogeneous in Early-Life Tuberous Sclerosis Complex.

  2021cites this paper
• Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.

  2021cites this paper
• Pharmacotherapy for Seizures in Tuberous Sclerosis Complex

  2021cites this paper
• Behavioral Symptoms May Correlate With the Load and Spatial Location of Tubers and With Radial Migration Lines in Tuberous Sclerosis Complex

  2021cites this paper
• Stop the Lights—Turning Off the Electricity in Tuberous Sclerosis

  2021cites this paper
• Can Preclinical Insights Give Us Hope for Effective Treatments for Epilepsy in 15q11-q13 Duplication Syndrome?

  2021cites this paper
• Epilepsy Management in Tuberous Sclerosis Complex: Existing and Evolving Therapies and Future Considerations.

  2021cites this paper
• Vagus nerve stimulation for drug-resistant epilepsy induced by tuberous sclerosis complex.

  2021cites this paper
• Symptom rates and profile clustering in tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)

  2021cites this paper
• Pulse Methylprednisolone with Oral Prednisolone versus Adrenocorticotropic Hormone in Children with West Syndrome: a Randomized Controlled Trial

  2021cites this paper
• Clinical profile of tuberous sclerosis complex patients with and without epilepsy: a need for awareness for early diagnosis

  2021cites this paper
• PEDIATRIC NEUROLOGY BRIEFS

  2021cites this paper